9640 Medical Center Drive
United States - Map
MacroGenics, Inc., a biopharmaceutical company, focuses on discovering and developing antibody-based therapeutics for the treatment of cancer primarily by modulating the human immune system, as well as various autoimmune disorders and infectious diseases. Its advanced clinical product candidate is Margetuximab, a monoclonal antibody that is in Phase III clinical trial, which targets human epidermal growth factor receptor 2-expressing tumors, including certain types of breast and gastroesophageal cancers. The company also develops Enoblituzumab, an antibody that is in Phase 1 clinical trial as monotherapy in multiple dose expansion cohorts; MGD006, a DART molecule that targets CD123 and CD3; MGD007, a DART molecule that targets glycoprotein A33 and CD3; MGD011, a DART molecule that targets CD19 and CD3, and develops for the treatment of B cell hematological malignancies; MGD009, a molecule in its B7-H3 franchise; and MGD013, a pre-clinical DART molecule enabling the co-blockade of two immune checkpoint molecules. In addition, the companys products comprise Teplizumab, an anti-CD3 monoclonal antibody for the treatment of type 1 diabetes; MGD010, a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells; and MGD014, a DART molecule that targets human immunodeficiency virus, or HIV-infected cells, and CD3-expressing T cells. MacroGenics, Inc. has collaborations with Janssen Biotech, Inc.; Takeda Pharmaceutical Company Ltd.; Les Laboratoires Servier and Institut de Recherches Servier; Gilead Sciences, Inc.; Boehringer Ingelheim GmbH; Pfizer, Inc.; and Green Cross Corp. MacroGenics, Inc. was founded in 2000 and is headquartered in Rockville, Maryland.
|MacroGenics, Inc.’s ISS Governance QuickScore as of May 1, 2016 is 7. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 8; Compensation: 7.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Scott Koenig M.D., Ph.D.,
Chief Exec. Officer, Pres and Director
|Mr. James Karrels ,
Chief Financial Officer, Sr. VP and Corp. Sec.
|Mr. Atul Saran ,
Sr. VP and Gen. Counsel
|Dr. Ezio Bonvini M.D.,
Sr. VP of Research
|Dr. Jon Wigginton M.D.,
Chief Medical Officer and Sr. VP of Clinical Devel.
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|